Inmaculada Alonso García

Lab Technician Neuroinmuno-
Repair Group (Lab i2-04)
National Hospital for Paraplegics-SESCAM
Toledo, Spain

1.- EDUCATION

- Certificate of higher education in Superior Clinical and Biomedical Laboratory Technician (2020). Juanelo Turriano High School, Toledo, Spain.

2.- RESEARCH AND PROFESSIONAL EXPERIENCE

- 2020: Internship student. Neuroinmuno-Repair group. National Hospital for Paraplegics-SESCAM, Toledo,Spain.

- 2021 to date: Superior Clinical and Biomedical Laboratory Technician. National Hospital for Paraplegics-SESCAM, Toledo,Spain.

3.-SCIENTIFIC COMMUNICATIONS IN NATIONAL/INTERNATIONAL CONFERENCES

-2022: Ortega, M.C., García-Arocha, J., Lebrón-Galán, R., Machín-Díaz, **I., García-Alonso**, I., Wojtas, B., Nieto-Díaz, M., Camacho-Toledano, C., Serrano-Regal, M.P., Calahorra, L., Kaminska, B., Clemente, D. **Deciphering the impact of myeloid-derived suppressor cell function on disease progression and neural tissue damage in Multiple Sclerosis.** FENS Fourm 2022. 2022. Paris, France. Poster

M.C. Ortega , J. Garcia-Arocha , R. Lebron-Galan , I. Machin-Diaz**, I. Alonso-García** , B. Wojtas , M. Nieto-Diaz , C. Camacho- Toledano , M.P. Serrano-Regal , L. Calahorra , B. Kaminska , D. Clemente. **Shedding light on the variability of the clinical course of multiple sclerosis: analysis of the influence of myeloid-derived suppressor cells on disease severity.** ECTRIMS 2022. 2022. Ámsterdam, Holanda. Poster

L. Calahorra , I. Machín- Díaz , **I. Alonso-García** , I. Pérez- Molina , J.M. García- Domínguez , R. Lebrón- Galán , V. Vila- del- Sol , H. Goicoechea-Briceño , J. García- Arocha , R. García- Montero , V. Galán , M.L. Martínez- Ginés , M.C. Ortega , C. Camacho- Toledano , M.P. Serrano- Regal , D. Clemente. **Cirtulating myeloid-derived supresor cells as a potential biomarker of an anti-inflammatory t-cell balance associated with improved relapse recovery in multiple sclerosis**. ECTRIMS 2022. 2022. Amsterdam, Holanda. Póster

M.P. Serrano-Regal , L. Calahorra **, I. Alonso García**, R. Grenningloh , U. Boschert , P. Haselmayer , M.C. Ortega , I. Machín Díaz , C. Camacho Toledano , J. García Arocha , D. Clemente**. Evobrutinib exerts a therapeutic action on EAE by increasing the peripheral and central classical dentritic cell number and maturation**. ECTRIMS 2022. Ámsterdam, Holanda. Poster

-2023: Diego Clemente, Celia Camacho-Toledano, María Cristina Ortega, Mari Paz Serrano-Regal, Leticia Calahorra, Isabel Machín-Díaz, **Inmaculada Alonso-García**, María Cabañas-Cotillas. **Investigación preclínica orientada: una fuente de respuestas para la resolución de problemas de salud asociados a la esclerosis múltiple.** I JORNADA DEL INSTITUTO DE INVESTIGACIÓN SANITARIA DE CASTILLA-LA MANCHA. Toledo, España. Ponencia

M.Serrano-Regal, L.Calahorra, **I.Alonso García**, U.Boschert, P.Haselmayer, M.C Ortega, I. Machín-Díaz, C. Camacho-Toledano, J.García-Arocha, D.Clemente. **Evobrutinib therapeutic response is associated with an increase in the number and maturation of peripheral and central classical dentritic cells**. ACTRIMS Forum 2023. San Diego, United States. Poster

D.Clemente, M.Serrano-Regal, L.Calahorra, **I.Alonso García**, U.Boschert, P.Haselmayer, M.C Ortega, I. Machín-Díaz, C. Camacho-Toledano, J.García-Arocha. **Evobrutinib therapeutic response is associated with an increase in the number and maturation of peripheral and central classical dentritic cells.** ANN. Boston, United States. Poster

M.P. Serrano-Regal, **I.Alonso-García**, C.Camacho-Toledano, I. Machín-Díaz, M.C. Ortega, L. Calahorra, D.Clemente. **Circulating myeloid-derived suppressor cells as a potential bioindicator of the endogenous myelin repair capacity in experimental multiple sclerosis**. IBRO 2023. Granada, Spain. Poster

Serrano-Regal, M.P., Calahorra L., **Alonso-García, I.,** Boschert, U., Haselmayer, P., Ortega, M.C., Machín-Díaz, I., Camacho-Toledano, C., García-Arocha, J., Clemente, D. **Evobrutinib treatment reduces the damage to the CNS and increases the number of classical dentritic cells in experimental multiple sclerosis.** IBRO 2023. Granada, Spain. Poster

L. Calahorra Melero, I. Machín-Díaz, **I. Alonso-García**, I. Pérez Molina, J. Manuel García Dominguez, R.Lebrón-Galán, V. Vila-del Sol, H. Goicochea, J. García-Arocha, R. García-Montero, V. Galan Sanchez-Seco, M. Luisa Martinez Gines, M. Cristina Ortega Muñoz, C. Camacho Toledano, M. Paz Serrano Regal, D.Clemente. **Circulating monocytic myeloid-derived suppressor cells but not Treg are potential biomarkers of a full relapse recovery in untreated multiple sclerosis patients.** ECTRIMS 2023. Milan, Italy. Poster

-**2024:** María Cabañas-Cotillas, Leticia Calahorra, Isabel Machín-Díaz, **Inmaculada Alonso-García**, Guillermo Martín-Ávila, José Manuel García-Domínguez, Haydee Goicochea-Briceño, Victoria Galán, María Cristina Ortega, Celia Camacho-Toledano, Mari Paz Serrano-Regal, María Luisa Martínez-Ginés, Yolanda Aladro, Diego Clemente. **Análisis del perfil inmunológico periférico en pacientes con esclerosis múltiple benigna: influencia del sexo y de la edad.** II JORNADAS DEL INSTITUTO DE INVESTIGACIÓN SANITARIA DE CASTILLA-LA MANCHA. Tomelloso, España. Ponencia.

4.- GRANTED RESEARCH PROJECTS

-2020: Analysis of the effect of Evobrutinib over Myeloid-Derived Suppressor Cells. Merck Serono EMB. **Total amount:** 308.991€ **Role:** Hired Lab technician .**PI**: Diego Clemente

-2018: Estudio de las células mieloides supresoras como biomarcadores del curso clínico de la esclerosis múltiple y su implicación en estrategias reparadoras de la vaina de mielina dañada. Asociación de Esclerosis Múltiple de Toledo (ADEM-TO). **Total amount:** 24.168 €.**Role:** Lab technician. **PI:** Diego Clemente

-2017: Células mieloides supresoras: diana terapéutica endógena para el tratamiento de la esclerosis múltiple. Fundación Galletas Coral; Aciturri Aeronáutica S.L; Vesuvius Ibérica; Embutidos y Jamones España e Hijos. **Total amount:** 16.400 €.**Role:** Lab technician. **PI:** Diego Clemente